Page 138 - 南京医科大学学报自然科学版
P. 138
第44卷第3期
·428 · 南 京 医 科 大 学 学 报 2024年3月
anti⁃oxidant,anti⁃apoptotic,anti⁃tumor,and/or anti⁃SARS⁃ 174:103703
CoV⁃2[J]. Life Sci,2022,309:121048 [43] IWAI T,SUGIMOTO M,PATEL H,et al. Anti⁃VEGF
[34] QIN W,ZOU J,HUANG Y B,et al. Pirfenidone facilitates antibody protects against alveolar exudate leakage caused
immune infiltration and enhances the antitumor efficacy by vascular hyperpermeability,resulting in mitigation of
of PD⁃L1 blockade in mice[J]. Oncoimmunology,2020,9 pneumonitis induced by immunotherapy[J]. Mol Cancer
(1):1824631 Ther,2021,20(12):2519-2526
[35] IWATA T,YOSHIDA S,FUJIWARA T,et al. Effect of [44] RAGHU G,REMY⁃JARDIN M,RICHELDI L,et al. Idio⁃
perioperative pirfenidone treatment in lung cancer pa⁃ pathic pulmonary fibrosis(an update)and progressive pul⁃
tients with idiopathic pulmonary fibrosis[J]. Ann Thorac monary fibrosis in adults:an official ATS/ERS/JRS/ALAT
Surg,2016,102(6):1905-1910 clinical practice guideline[J]. Am J Respir Crit Care
[36] QIN W,LIU B,YI M X,et al. Antifibrotic agent pirfeni⁃ Med,2022,205(9):18-47
done protects against development of radiation ⁃ induced [45] PENG D D,FU M Y,WANG M N,et al. Targeting TGF⁃β
pulmonary fibrosis in a murine model[J]. Radiat Res, signal transduction for fibrosis and cancer therapy[J].
2018,190(4):396-403 Mol Cancer,2022,21(1):104
[37] BRANCO H,OLIVEIRA J,ANTUNES C,et al. Pirfeni⁃ [46] CAGLEVIC C,GRASSI M,RAEZ L,et al. Nintedanib in
done sensitizes NCI ⁃ H460 non ⁃ small cell lung cancer non⁃small cell lung cancer:from preclinical to approval
cells to paclitaxel and to a combination of paclitaxel with [J]. Ther Adv Respir Dis,2015,9(4):164-172
carboplatin[J]. Int J Mol Sci,2022,23(7):3631 [47] SHIRATORI T,TANAKA H,TABE C,et al. Effect of ninte⁃
[38] YAMAMOTO Y,YANO Y,KUGE T,et al. Safety and danib on non⁃small cell lung cancer in a patient with id⁃
effectiveness of pirfenidone combined with carboplatin ⁃ iopathic pulmonary fibrosis:a case report and literature
based chemotherapy in patients with idiopathic pulmo⁃ review[J]. Thorac Cancer,2020,11(6):1720-1723
nary fibrosis and non⁃small cell lung cancer:a retrospec⁃ [48] RIMNER A,MOORE Z R,LOBAUGH S,et al. Rando ⁃
tive cohort study[J]. Thorac Cancer,2020,11(11): mized phase 2 placebo⁃controlled trial of nintedanib for
3317-3325 the treatment of radiation pneumonitis[J]. Int J Radiat
[39] AMANO H,MATSUI Y,HATANAKA K,et al. VEGFR1⁃ Oncol Biol Phys,2023,116(5):1091-1099
tyrosine kinase signaling in pulmonary fibrosis[J]. In⁃ [49] OTSUBO K,KISHIMOTO J,ANDO M,et al. Nintedanib
flamm Regen,2021,41(1):16 plus chemotherapy for nonsmall cell lung cancer with idio⁃
[40] 丁清清,管 蔚,丁永斌,等. 结直肠癌中 FcγRⅡ和 pathic pulmonary fibrosis:a randomised phase 3 trial[J].
VEGF⁃A的表达与临床意义[J]. 南京医科大学学报(自 Eur Respir J,2022,60(6):2200380
然科学版),2014,34(2):179-182 [50] FANG W F,HUANG Y H,GAN J D,et al. Nintedanib
[41] BARRATT S L,FLOWER V A,PAULING J D,et al. effect in osimertinib⁃induced interstitial pneumonia[J]. J
VEGF(vascular endothelial growth factor)and fibrotic Thorac Oncol,2020,15(3):34-35
lung disease[J]. Int J Mol Sci,2018,19(5):1269 [51] TU J Y,XU H R,MA L,et al. Nintedanib enhances
[42] NOZAWA K,TAKATSUKA D,ENDO Y,et al. Associa⁃ the efficacy of PD⁃L1 blockade by upregulating MHC⁃I
tion between bevacizumab with cancer drug therapies and and PD⁃L1 expression in tumor cells[J]. Theranostics,
drug⁃induced interstitial lung disease in patients with solid 2022,12(2):747-766
tumor:a systematic review and meta⁃analysis of random⁃ [收稿日期] 2023-08-25
ized clinical trials[J]. Crit Rev Oncol Hematol,2022, (本文编辑:陈汐敏)